Welcome!

News Feed Item

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

 

Summary

 

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

 

For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.

 

Scope

 

- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of drug performance.

- Obtain sales forecast for drugs from 2012-2022 in India.

1 Table of Contents

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Symptoms 16

3.3 Prognosis 17

3.4 Quality of Life 18

4 Disease Management 19

4.1 Treatment Overview 20

4.2 India 25

4.2.1 Diagnosis 25

4.2.2 Clinical Practice 25

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles - Major Brands 29

5.3.1 Remicade (infliximab) 29

5.3.2 Other Marketed Products 35

6 Opportunity and Unmet Need 36

6.1 Overview 36

6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37

6.3 More Therapies for Anti-TNF-Refractory Patients 38

6.4 Unmet Needs Gap Analysis 39

6.5 Targeted Therapies 40

6.6 Predictive Tools for Early Diagnosis and Treatment 41

7 Pipeline Assessment 42

7.1 Overview 42

7.2 Promising Drugs in Clinical Development 42

7.3 Other Late-Stage Pipeline Products 44

7.3.1 Cx601 44

7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46

8 Market Outlook 51

8.1 Global Markets 51

8.1.1 Drivers and Barriers - Global Issues 51

9 India 56

9.1 Forecast 56

9.2 Key Events 58

9.3 Drivers and Barriers 59

9.3.1 Driver: Continued investment in the national healthcare system and services 59

9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59

9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60

9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60

9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61

10 Appendix 62

10.1 Bibliography 62

10.2 Abbreviations 67

10.3 Methodology 71

10.4 Forecasting Methodology 71

10.4.1 Diagnosed CD Patients 71

10.4.2 Percent Drug-Treated Patients 72

10.4.3 Drugs Included in Each Therapeutic Class 72

10.4.4 General Pricing Assumptions 72

10.4.5 Individual Drug Assumptions 74

10.4.6 Generic Erosion 74

10.5 Physicians and Specialists Included in This Study 75

10.6 Primary Research - Prescriber Survey 76

10.7 About the Authors 77

10.7.1 Author/Reviewer 77

10.7.2 Global Head of Healthcare 77

10.8 About GlobalData 78

10.9 Disclaimer 78

 

1.1 List of Tables

 

Table 1: Symptoms of CD 17

Table 2: Treatment Guidelines for CD 21

Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23

Table 4: Leading Branded Drugs Used to Treat CD 29

Table 5: Product Profile - Remicade 31

Table 6: Remicade SWOT Analysis, 2013 34

Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35

Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37

Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40

Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42

Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43

Table 12: Product Profile - Cx601 45

Table 13: Cx601 SWOT Analysis, 2013 46

Table 14: Product Profile - RHB-104 48

Table 15: RHB-104 SWOT Analysis, 2013 50

Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51

Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57

Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58

Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59

Table 20: Physicians Surveyed, By Country 76

 

1.2 List of Figures

 

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13

Figure 2: Potential Biologic Drug Targets for CD 16

Figure 3: Patient Care Path for CD 22

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43

Figure 5: Sales for CD in India by Drug Class, 2012-2022 58

 

 

To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, will discuss the importance of WebRTC and how it enables companies to fo...
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
SYS-CON Events announced today TechTarget has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. TechTarget is the Web’s leading destination for serious technology buyers researching and making enterprise technology decisions. Its extensive global networ...
As cloud and storage projections continue to rise, the number of organizations moving to the cloud is escalating and it is clear cloud storage is here to stay. However, is it secure? Data is the lifeblood for government entities, countries, cloud service providers and enterprises alike and losing or exposing that data can have disastrous results. There are new concepts for data storage on the horizon that will deliver secure solutions for storing and moving sensitive data around the world. ...
Korean Broadcasting System (KBS) will feature the upcoming 18th Cloud Expo | @ThingsExpo in a New York news documentary about the "New IT for the Future." The documentary will cover how big companies are transmitting or adopting the new IT for the future and will be filmed on the expo floor between June 7-June 9, 2016, at the Javits Center in New York City, New York. KBS has long been a leader in the development of the broadcasting culture of Korea. As the key public service broadcaster of Korea...
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
As machines are increasingly connected to the internet, it’s becoming easier to discover the numerous ways Industrial IoT (IIoT) is helping to shape the business world. This is exactly why we have decided to take a closer look at this pervasive movement and to examine the desire to connect more things! Now if you need a refresher on IIoT and how it is changing the world, take a moment and listen to Greg Gorbach with ARC Advisory Group. Gorbach believes, "IIoT will significantly change the worl...
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit y...
Cloud computing changed data analytics for good. It enabled companies to drastically decrease resources and architecture previously assigned with business intelligence departments. It also enabled laymen to run advanced business analytics. Cloud was also the architecture of choice for storing and processing big data. Data piling is a continuous process, which is going to explode with emerging Internet of Things concept. Answer to this issue developers found in new concept called fog computing. ...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.